ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $59.54, for a total value of $23,816.00. Following the sale, the vice president now owns 83,478 shares in the company, valued at approximately $4,970,280.12. This trade represents a 0.48 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Meredith Cook also recently made the following trade(s):
- On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total value of $21,568.00.
ANI Pharmaceuticals Trading Down 2.9 %
ANIP stock traded down $1.73 during trading on Friday, hitting $57.94. The company had a trading volume of 218,474 shares, compared to its average volume of 182,655. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a 50 day simple moving average of $57.08 and a 200-day simple moving average of $58.23. The firm has a market capitalization of $1.22 billion, a P/E ratio of -105.35 and a beta of 0.74. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.
Institutional Trading of ANI Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of the stock. US Bancorp DE grew its stake in ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after purchasing an additional 531 shares in the last quarter. KBC Group NV lifted its holdings in shares of ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after buying an additional 600 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of ANI Pharmaceuticals during the 4th quarter worth $166,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock valued at $177,000 after buying an additional 579 shares during the period. Finally, Rafferty Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $200,000. Institutional investors own 76.05% of the company's stock.
Analysts Set New Price Targets
A number of analysts recently issued reports on ANIP shares. HC Wainwright restated a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 target price on the stock. StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 5th. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $77.71.
Get Our Latest Stock Report on ANI Pharmaceuticals
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
See Also
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
